Pierre Beauparlant Venture Partner

Pierre Beauparlant, Ph.D, has more than 25 years of experience in large pharma and development stage, venture backed biopharmaceutical companies with expertise from discovery through commercialization.  Dr. Beauparlant has served as CEO of companies of the Sanderling portfolio, including PreciThera Inc. an early-stage company specialized in developing biologics for rare musculoskeletal diseases and SpecificiT Pharma Inc. a clinical stage company developing cellular therapies for cancer. Previously he served as Medical Therapeutic Head – Hematology at Novartis Pharmaceuticals Canada. During his work at Novartis, Pierre oversaw 46 clinical trials and supported Drug Regulatory Affairs and Market Access departments in their submissions to regulatory authorities. Prior to Novartis, Dr. Beauparlant held roles of increasing responsibility at Gemin X Pharmaceuticals Inc., a venture-backed clinical stage oncology company sold to Cephalon in 2011. As Vice President Research and Scientific Development, he held responsibilities for advancing drug discovery projects to identify new chemical entities for the treatment of cancer, business development, in-licensing, and intellectual property. Dr. Beauparlant holds a Ph.D. from McGill University.